Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/5/2009

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009.

Based upon the Priority Review designation granted by the FDA for Cadence's New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), the company accelerated its commercial readiness activities during the third quarter of 2009. Commenting on the third quarter achievements, Ted Schroeder, President and CEO of Cadence stated, "We are extremely pleased with the progress we have made in building our commercial infrastructure, including the recruitment of a highly experienced commercial leadership team to launch Acetavance, if approved by the FDA."

Financial Results

For the three months ended September 30, 2009, Cadence reported a net loss of $11.4 million, or $0.23 per share, compared to a net loss of $13.7 million, or $0.36 per share, for the same period in 2008. Operating expenses for the three months ended September 30, 2009 decreased $2.4 million to $11.3 million, from the $13.7 million reported for the comparable period in 2008. The decline in operating expenses during the current year was primarily the result of a reduction in research and development costs as the company completed its clinical development program for Acetavance in early 2009 and submitted an NDA for this product candidate in May 2009. Further, in March 2009, the company discontinued the development program for its omiganan product candidate. Partially offsetting this reduction is an increase in sales and marketing expenses as the company focused significant resources on establishing its commercial infrastructure in preparation for the potential commercialization of Acetavance. More specifically, during the three months ended September 30, 2009, Cadence hired its sales management team for the potential launch of Acetavance, if approved, and is currently recruiting sales representatives contingent on FDA approval. Cadence also increased spending related to the development of marketing materials and programs during the three months ended September 30, 2009. In addition, general and administrative expenses increased during the current quarter primarily due to increased personnel costs, including an additional $0.6 million in stock-based compensation charges.

For the nine months ended September 30, 2009, Cadence reported a net loss of $30.2 million, or $0.63 per share, compared to a net loss of $43.1 million, or $1.18 per share, for the same period in 2008. Operating expenses for the nine months ended September 30, 2009 were $29.4 million, a decrease of $13.6 million from the $43.0 million reported for the comparable period in 2008. The decrease in current year expenses is primarily due to a reduction in research and development costs as a result of the company's discontinuation of the development program for its omiganan product candidate in March 2009, the completion of its clinical development program for Acetavance in early 2009, and the submission of its NDA for Acetavance in May 2009. Partially offsetting this reduction is an increase in sales and marketing expenses in 2009 as the company began establishing its commercial and supply operation functions in preparation for the potential commercialization of Acetavance. General and administrative expenses increased during the current year primarily due to increased personnel costs, including an additional $0.8 million in stock-based compensation charges.

As of September 30, 2009, Cadence held cash, cash equivalents and short-term investments of $96.6 million.

Conference Call and Webcast on November 5, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)

Cadence management will host a conference call on November 5, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing 888-811-5448 (domestic) or 913-312-4376 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance (intravenous acetaminophen), an investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "expects," "anticipates," "plans," "will," and "assuming," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding: the company's efforts to accelerate the development of its commercial and supply operations infrastructure, the likelihood of obtaining regulatory approval for Acetavance in a timely manner, or at all, and any financial estimates or projections. The inclusion of forward-looking statements such as these should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: the possibility that the FDA may not complete its review of Cadence's NDA for Acetavance by the PDUFA goal date, or that the FDA may not approve the NDA if it determines that the clinical, non-clinical or other data submitted in the NDA are not adequate to support the safety or efficacy of this product candidate; the possibility that pre-approval inspections by the FDA of the site where Acetavance is manufactured, or Cadence's clinical trial sites, may raise issues that must be resolved prior to obtaining approval of the NDA; the risk that increased attention to drug safety issues may result in a more cautious approach by the FDA, which could delay the completion of the review process for the Acetavance NDA, or result in limitations in the indications for use or the inclusion of unfavorable information in the labeling for this product candidate; intense competition from existing and new products, which could diminish the commercial potential for Acetavance; the possibility that the patent rights covering Acetavance may not be sufficient to preclude other intravenous formulations of acetaminophen from being developed by competitors; the company's dependence on Acetavance, which is Cadence's only product candidate; the potential for Cadence to require substantial additional funding in order to obtain regulatory approval for and commercialize Acetavance, and the risk that the company may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contact:    William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                Phone : 858-436-1400



                           CADENCE PHARMACEUTICALS, INC.
                           (a development stage company)
                        CONDENSED STATEMENTS OF OPERATIONS
                                    (unaudited)

                          Three Months Ended          Nine Months Ended
                             September 30,              September 30,
                          ------------------          -----------------
                          2009          2008          2009         2008
                          ----          ----          ----         ----
    Operating expenses:
      Research and
       development     $4,924,778   $10,241,943   $15,144,099   $32,463,211
      Sales and
       marketing        2,608,441       664,143     4,330,695     2,175,120
      General and
       administrative   3,762,851     2,754,064     9,549,203     8,323,996
      Other                  (944)          509       412,141        28,766
                             ----           ---       -------        ------
        Total
         operating
         expenses      11,295,126    13,660,659    29,436,138    42,991,093
                       ----------    ----------    ----------    ----------

    Loss from
     operations       (11,295,126)  (13,660,659)  (29,436,138)  (42,991,093)

    Other (expense)
     income, net         (145,979)      (88,336)     (742,411)      (71,653)
                         --------       -------      --------       -------

    Net loss         $(11,441,105) $(13,748,995) $(30,178,549) $(43,062,746)
                     ============  ============  ============  ============


    Basic and
     diluted net loss
     per share(1)          $(0.23)       $(0.36)       $(0.63)       $(1.18)
                           ======        ======        ======        ======


    Shares used to
     compute basic
     and diluted
     net loss per
     share(1)          50,364,493    38,116,063    48,189,177    36,371,272
                       ==========    ==========    ==========    ==========



    (1)  As a result of the issuance of 12,039,794 shares of common stock
         pursuant to a private placement in the first quarter of 2009 and
         9,240,307 shares of common stock pursuant to an effective shelf
         registration in the first quarter of 2008, there is a lack of
         comparability in the per share amounts between the 2009 and 2008
         periods presented.

                           CADENCE PHARMACEUTICALS, INC.
                           (a development stage company)
                             CONDENSED BALANCE SHEETS

                                                   September 30,  December 31,
                                                       2009           2008
                                                       ----           ----
                                                    (unaudited)
                     Assets
    Current assets:
      Cash, cash equivalents and short-term
       investments                                   $96,552,282  $47,627,246
      Restricted cash                                  1,695,696    2,195,696
      Prepaid expenses and other current assets          569,427      219,674
                                                         -------      -------
        Total current assets                          98,817,405   50,042,616

    Property and equipment, net                        6,826,161    4,477,020
    Restricted cash                                      189,738      537,586
    Other assets                                          25,082       90,792
                                                          ------       ------
        Total assets                                $105,858,386  $55,148,014
                                                    ============  ===========

      Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable                                 2,997,956   $4,877,854
      Accrued liabilities                              5,599,841    9,063,310
      Current portion of long-term debt                6,229,049    7,694,173
      Other current liabilities                           22,048       22,048
                                                          ------       ------
        Total current liabilities                     14,848,894   21,657,385

    Deferred rent                                        725,625      952,274
    Long-term debt, less current portion and
     discount                                          1,650,996    6,098,113
    Total stockholders' equity                        88,632,871   26,440,242
                                                      ----------   ----------
        Total liabilities and stockholders' equity  $105,858,386  $55,148,014
                                                    ============  ===========



SOURCE Cadence Pharmaceuticals, Inc.


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Jamaica (PRWEB) , ... April 30, 2016 , ... ... and Duane Boise, President and CEO of EMED, today signed a multifaceted agreement ... , EMED and the Northern Caribbean University Department of Natural and Applied Sciences, ...
(Date:4/30/2016)... ... 2016 , ... “Aging well is a challenge for all of us, but there are things we can do ... . “Research is showing more and more that there are simple, yet important steps that ... we age.” Top priorities Dr. Kohli’s recommends for her patients include;, , ...
(Date:4/29/2016)... ... 2016 , ... World Patent Marketing , a vertically ... automotive invention that improves the storage features of a pick up truck. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Over the next five ...
(Date:4/29/2016)... ... ... In an article published April 16th on the New York ... injections, which she underwent in order to feel more at home at this year’s ... article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say they’ve ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System ... Medical Education (ACGME) that it has received accreditation for its residency program on ... residency programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... 2016  Marking its one year anniversary since ... cancer risk test, Color Genomics announced ... highly impact the most common hereditary cancers affecting ... Test analyzes hereditary cancer risks for breast, colorectal, ... The Color Test is physician ordered and includes ...
Breaking Medicine Technology: